Mapracorat
Sponsors
Bausch & Lomb Incorporated, Bayer
Conditions
Atopic DermatitisCataractConjunctivitis, AllergicCorneal Endothelial Cell ChangesEczemaInflammationPainSurgery
Phase 1
Phase 2
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
CompletedNCT01289431
Start: 2011-02-28End: 2011-04-30Updated: 2020-09-04
Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)
CompletedNCT01359787
Start: 2011-05-31End: 2011-09-30Updated: 2015-01-21
HPA Axis Study in Japanese Adults
CompletedNCT01407510
Start: 2011-05-09End: 2012-04-15Updated: 2023-09-21
HPA Axis Study in Adults
CompletedNCT01408511
Start: 2011-07-19End: 2011-12-21Updated: 2023-10-31
Phase 3
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
CompletedNCT01230125
Start: 2010-11-30End: 2011-08-31Updated: 2020-09-03
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
TerminatedNCT01298752
Start: 2011-02-28End: 2011-11-30Updated: 2020-09-03
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
CompletedNCT01591161
Start: 2012-07-31End: 2013-07-31Updated: 2020-09-03
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
CompletedNCT01591655
Start: 2012-07-31End: 2013-10-31Updated: 2020-09-03